Anna T. Jonasova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Journal: Haematologica

Published: June 22, 2026

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Journal: Blood cancer journal

Published: February 03, 2026

Characterization of neocentromeric marker chromosome derived from chromosome 11: a rare entity in four patients with acute leukemia.

Characterization of neocentromeric marker chromosome derived from chromosome 11: a rare entity in four patients with acute leukemia.

Journal: Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology

Published: January 15, 2026

Variant-specific SF3B1 mutations drive distinct splicing and mitochondrial dysfunction in myelodysplastic neoplasms.

Variant-specific SF3B1 mutations drive distinct splicing and mitochondrial dysfunction in myelodysplastic neoplasms.

Journal: Human genomics

Published: January 06, 2026

Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML.

Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML.

Journal: Redox biology

Published: October 21, 2025

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.

Journal: Blood cancer journal

Published: September 18, 2025

Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic.

Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 14, 2025

Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure.

Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure.

Journal: Journal of clinical immunology

Published: April 08, 2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Journal: Blood advances

Published: February 24, 2025

Dysregulation of transposable elements and PIWI-interacting RNAs in myelodysplastic neoplasms.

Dysregulation of transposable elements and PIWI-interacting RNAs in myelodysplastic neoplasms.

Journal: Biomarker research

Published: October 15, 2024

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.

Journal: British journal of haematology

Published: May 11, 2024

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

Journal: The Lancet. Haematology

Published: May 10, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026